Literature DB >> 18209053

Antigen release kinetics in the phagosome are critical to cross-presentation efficiency.

Shanshan W Howland1, K Dane Wittrup.   

Abstract

Cross-presentation of exogenous Ags in MHC class I molecules by dendritic cells is the underlying basis for many developing immunotherapies and vaccines. In the phagosome-to-cytosol pathway, Ags in phagocytosed particles must become freely soluble before being exported to the cytosol, but the kinetics of this process has yet to be fully appreciated. We demonstrate with a yeast vaccine model that the rate of Ag release in the phagosome directly affects cross-presentation efficiency, with an apparent time limit of approximately 25 min postphagocytosis for Ag release to be productive. Ag expressed on the yeast surface is cross-presented much more efficiently than Ag trapped in the yeast cytosol by the cell wall. The cross-presentation efficiency of yeast surface-displayed Ag can be increased by the insertion of linkers susceptible to cleavage in the early phagosome. Ags indirectly attached to yeast through Ab fragments are less efficiently cross-presented when the Ab dissociation rate is extremely slow.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18209053      PMCID: PMC2820304          DOI: 10.4049/jimmunol.180.3.1576

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  44 in total

1.  NOX2 controls phagosomal pH to regulate antigen processing during crosspresentation by dendritic cells.

Authors:  Ariel Savina; Carolina Jancic; Stephanie Hugues; Pierre Guermonprez; Pablo Vargas; Ivan Cruz Moura; Ana-Maria Lennon-Duménil; Miguel C Seabra; Graça Raposo; Sebastian Amigorena
Journal:  Cell       Date:  2006-07-14       Impact factor: 41.582

Review 2.  Adoptive immunotherapy for cancer: building on success.

Authors:  Luca Gattinoni; Daniel J Powell; Steven A Rosenberg; Nicholas P Restifo
Journal:  Nat Rev Immunol       Date:  2006-05       Impact factor: 53.106

Review 3.  Hepatitis C vaccines: Inducing and challenging memory T cells.

Authors:  Masaaki Shiina; Barbara Rehermann
Journal:  Hepatology       Date:  2006-06       Impact factor: 17.425

4.  Human dendritic cell interactions with whole recombinant yeast: implications for HIV-1 vaccine development.

Authors:  Michelle A Barron; Naomi Blyveis; Samuel C Pan; Cara C Wilson
Journal:  J Clin Immunol       Date:  2006-05-13       Impact factor: 8.317

Review 5.  DNA vaccines: successes and limitations in cancer and infectious disease.

Authors:  Devin B Lowe; Michael H Shearer; Ronald C Kennedy
Journal:  J Cell Biochem       Date:  2006-05-15       Impact factor: 4.429

Review 6.  Recent developments in therapeutic cancer vaccines.

Authors:  Michael A Morse; Stephen Chui; Amy Hobeika; H Kim Lyerly; Timothy Clay
Journal:  Nat Clin Pract Oncol       Date:  2005-02

7.  Cross-presentation of HLA class I epitopes from influenza matrix protein produced in Saccharomyces cerevisiae.

Authors:  Andreas Wadle; Gerhard Held; Frank Neumann; Sascha Kleber; Beate Wuellner; Anne Marie Asemissen; Boris Kubuschok; Carmen Scheibenbogen; Tanja Breinig; Andreas Meyerhans; Christoph Renner
Journal:  Vaccine       Date:  2006-06-14       Impact factor: 3.641

Review 8.  Vaccines for tumour prevention.

Authors:  Pier-Luigi Lollini; Federica Cavallo; Patrizia Nanni; Guido Forni
Journal:  Nat Rev Cancer       Date:  2006-03       Impact factor: 60.716

Review 9.  Therapeutic cancer vaccines.

Authors:  Pramod K Srivastava
Journal:  Curr Opin Immunol       Date:  2006-02-07       Impact factor: 7.486

Review 10.  HIV vaccines.

Authors:  Andrew J McMichael
Journal:  Annu Rev Immunol       Date:  2006       Impact factor: 28.527

View more
  12 in total

1.  A proteasome-dependent, TAP-independent pathway for cross-presentation of phagocytosed antigen.

Authors:  Nawel Merzougui; Roland Kratzer; Loredana Saveanu; Peter van Endert
Journal:  EMBO Rep       Date:  2011-12-01       Impact factor: 8.807

Review 2.  Engineering synthetic vaccines using cues from natural immunity.

Authors:  Darrell J Irvine; Melody A Swartz; Gregory L Szeto
Journal:  Nat Mater       Date:  2013-11       Impact factor: 43.841

Review 3.  Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines.

Authors:  Stacey L Demento; Alyssa L Siefert; Arunima Bandyopadhyay; Fiona A Sharp; Tarek M Fahmy
Journal:  Trends Biotechnol       Date:  2011-04-02       Impact factor: 19.536

Review 4.  Engineering nano- and microparticles to tune immunity.

Authors:  James J Moon; Bonnie Huang; Darrell J Irvine
Journal:  Adv Mater       Date:  2012-05-29       Impact factor: 30.849

Review 5.  Regulation of Antigen Export to the Cytosol During Cross-Presentation.

Authors:  Marine Gros; Sebastian Amigorena
Journal:  Front Immunol       Date:  2019-01-28       Impact factor: 7.561

Review 6.  MHC molecules and microbial antigen processing in phagosomes.

Authors:  Lakshmi Ramachandra; Daimon Simmons; Clifford V Harding
Journal:  Curr Opin Immunol       Date:  2009-02-11       Impact factor: 7.486

7.  The role of phagosomal pH on the size-dependent efficiency of cross-presentation by dendritic cells.

Authors:  Kenny K Tran; Hong Shen
Journal:  Biomaterials       Date:  2008-12-16       Impact factor: 12.479

8.  Acetalated dextran is a chemically and biologically tunable material for particulate immunotherapy.

Authors:  Kyle E Broaders; Joel A Cohen; Tristan T Beaudette; Eric M Bachelder; Jean M J Fréchet
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-24       Impact factor: 11.205

9.  Inducing efficient cross-priming using antigen-coated yeast particles.

Authors:  Shanshan W Howland; Takemasa Tsuji; Sacha Gnjatic; Gerd Ritter; Lloyd J Old; Karl Dane Wittrup
Journal:  J Immunother       Date:  2008-09       Impact factor: 4.456

10.  Just-in-time vaccines: Biomineralized calcium phosphate core-immunogen shell nanoparticles induce long-lasting CD8(+) T cell responses in mice.

Authors:  Weibin Zhou; Albanus O Moguche; David Chiu; Kaja Murali-Krishna; François Baneyx
Journal:  Nanomedicine       Date:  2013-11-22       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.